Abbvie Inc.

Abbott Laboratories Corporation

Abbott Gmbh & Co Kg

Michael M Friedman

Kristine E Frank

Neil Wishart

Eric C Breinlinger

Noel S Wilson

Dawn M George

Augustine Osuma

Anil Vasudevan

David J Calderwood

Maria A Argiriadi

Lu Wang

Justin D Dietrich

Kelly Mullen

Grier A Wallace

David Ihle

Kent D Stewart

Michael Z Hoemann

Michael Morytko

Biqin C Li

Nathan Josephsohn

Anna M Ericsson

Kurt Ritter

Lee Daniel Arnold

Gavin C Hirst

Paul Rafferty

Kevin Patrick Cusack

Andrew Burchat

Gagandeep K Somal

J Martin Herold

Eric R Goedken

Kevin R Woller

Kenton L Longenecker

Thomas D Gordon

Adrian Hobson

Jeffrey W Voss

Xiangdong Xu

Phil B Cox

Dominique Bonafoux

David Andrew Kinsman

Gloria Y Lo Schiavo

Huan-Qui Li

Ann Marie Rowley

Stacy A Van Epps

Raymond Huntley

Bryan A Fiamengo

Shuhui Chen

Stevan Wakefield Djuric

Marlon D Cowart

Arthur Gomtsyan

Michael R Schrimpf

George S Sheppard

Jerome F Daanen

Mikhail A Chafeev

Huaqing Liu

Wentao Wu

Richard W Dixon

Robert G Schmidt

Marc J Scanio

Martine Barth

Jianfei Wang

Didier Thomas

Heather M Davis

Lei Wang

Zhi Wang

Xiaoyun Wu

Martin E Hayes

Tatyana Dekhtyar

Fabrice Guillier

Iok Chan Ng

M-akhteruzzaman Molla

Bin Li

Artour Gomtsian

Matthew H Katcher

Dominique Potin

Philip Cox

Jennifer Van Camp

Wei Qiu

Wouter Iwema Bakker

Linlin Dai

Jeremy Edmunds

Thomas R Vargo

Amanda W Dombrowski

Matthew P Webster

Mikhail Chafeev

Andrew J Little

Gloria Y LoSchiavo

Ellen Yulin Tsai Chien

David J Hardee

Nathan S Josephsohn

Michael J Morytko

Teresa Ng

M-Akhteruzz Molla

Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R2, R, R, R, X, X, X, X, X, nad n are as defined herein, pharmaeceutical compositions 2C X, and n are as defined herein, pharmaceutical compositions comprising same, and methods of preparation and use. 

Inhibitors of tyrosine kinase 2 mediated signaling

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions. 

Heterocyclic kinase inhibitors

The disclosure provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

Indazolones as modulators of TNF signaling

The invention provides tricyclic heterocyclic compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention may be useful for treating immunological and oncological conditions.

Tricyclic modulators of TNF signaling

The invention provides compounds of Formula (I) and Formula (II) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Tricyclic compounds

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

Indazolones as modulators of tnf signaling

This disclosure relates to: (a) compounds and salts of formula (I), formula (II), formula (III), and formula (IV), that, inter alia, inhibit RSV infection and/or replication; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions. 

Substituted cyanoguanidines as oral anti-virals

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Primary carboxamides as BTK inhibitors

The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Heterocyclic nuclear hormone receptor modulators

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

Growing community of inventors

Newton, MA, United States of America

Michael M Friedman